A regulator's decision to approve a drug for marketing is based on it having a ______ of benefits and risks within the conditions specified in the product labeling.

A regulator's decision to approve a drug for marketing is based on it having a ______ of benefits and risks within the conditions specified in the product labeling.

• A. Satisfactory balance
• B. Balanced incentives
• C. Market likelihood
• D. Production costs

Answer: (A)

Regulatory approval hinges on a satisfactory balance of benefits and risks for the intended use described in the product labeling. The labeling defines who should use the drug, for what condition, dosing, duration, and required monitoring. When the evidence shows that the therapeutic benefits meaningful to patients outweigh the risks within those labeled conditions, the balance is considered favorable, supporting approval. The other ideas don’t fit because this decision isn’t about economic incentives, chances of commercial success, or manufacturing costs. It’s about safety and efficacy in relation to how the drug will be used and monitored under the labeling.

Regulatory approval hinges on a satisfactory balance of benefits and risks for the intended use described in the product labeling. The labeling defines who should use the drug, for what condition, dosing, duration, and required monitoring. When the evidence shows that the therapeutic benefits meaningful to patients outweigh the risks within those labeled conditions, the balance is considered favorable, supporting approval.

The other ideas don’t fit because this decision isn’t about economic incentives, chances of commercial success, or manufacturing costs. It’s about safety and efficacy in relation to how the drug will be used and monitored under the labeling.